Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radical MP (Member of Parliament) helps French industry "out of its tunnel":

This article was originally published in Clinica

Executive Summary

The French parliamentary medical technologies working group (see Clinica No 918, p 3) is to be headed by Bernard Charles, president of the Radical Green Citizens party. Mr Charles has taken a personal interest in this sector of French industry and has recently described it as "gradually emerging from a tunnel". The appointment has been welcomed by the French medical device industry association, SNITEM, which has developed a good working relationship with the MP. It has also been applauded by the US Advanced Medical Technology Association, AdvaMed, which is actively trying to help shape French policies (see this issue page 5).

You may also be interested in...



Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.

Flu Vaccine Leader Sanofi Joins Fight Against COVID-19

As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.

Sobi Reaps Benefits From Acquisitions, Commercial Focus

Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.

  

Topics

UsernamePublicRestriction

Register

MT076909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel